News & Trends - Pharmaceuticals

RACGP warns Australians not to use hydroxychloroquine to treat COVID-19

Health Industry Hub | May 22, 2020 |
[Total: 1    Average: 4/5]

Pharma News: The Royal Australian College of General Practitioners (RACGP) has urged Australians not to seek out or use hydroxychloroquine to “cure” or “prevent” the COVID-19 virus.

An Australian clinical trial is now underway to determine whether the drug can help prevent the COVID-19 virus. However, there is still insufficient evidence that hydroxychloroquine can be used to combat the pandemic.

Hydroxychloroquine is a medication used to prevent and treat malaria and is also used in the treatment of conditions including rheumatoid arthritis and lupus. A similar drug chloroquine is derived from the quinoline molecule and is also used to treat various types of malaria.

RACGP President Dr Harry Nespolon said that the drugs should not be used to assist in preventing or treating COVID-19.

Register FREE & join 22,000+ industry professionals in reading the latest industry news & engaging content from Health Industry Hub, the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

“It is positive news that this new Australian clinical trial featuring 2,000 frontline healthcare workers is now open for volunteers. It’s one of several trials underway but the evidence-base is simply not there to say that this drug can be used to prevent the COVID-19 virus.

“There is quite simply insufficient evidence that hydroxychloroquine and chloroquine can ‘cure’ COVID-19. So the drugs should not be provided to patients outside of a formal randomised clinical trial and I also strongly advise against acquiring these drugs on the dark web or anywhere else.

“When prescribing and using any drug we need to rely on scientific evidence and make careful determinations of whether these drugs or any other can help combat the COVID-19 pandemic.

You may also like PRIME Awards 2020 call for entries – the only awards program dedicated to recognising excellence within Australian healthcare communications, is now open for entries.

“We need to exercise extreme caution here. That is one of the reasons why the RACGP supported the Therapeutic Goods Administration’s (TGA) recent move to place tight new restrictions on who can write prescriptions for these drugs.

“Some studies have also indicated an elevated risk of serious adverse effects like cardiac arrest.”

“Before trying to source this drug consider this simple fact. Off-label use of hydroxychloroquine can have significant consequences for those who are normally prescribed the drug and really need it. If people rush out and acquire hydroxychloroquine patients may not be able access it due to inappropriate use reducing stock levels.

“Let me be 100% clear, we need to ensure there is stock available for those who actually need this drug right now.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Human Resources

Human Resource Management - MSD revealed as finalist in Australian HR Awards

MSD revealed as finalist in Australian HR Awards

Health Industry Hub | July 13, 2020 |

The Australian HR Awards celebrates the outstanding achievements of the country’s top Human Resources leaders, companies and teams. MSD reveals […]

More


News & Trends - Medical Technology

MedTech News - Radiologists report a significant drop in diagnostic imaging services during COVID-19

Radiologists report a significant drop in diagnostic imaging during COVID-19

Health Industry Hub | July 13, 2020 |

MedTech News: Clinical radiologists are concerned that patients are delaying their required imaging procedures and encourage people to continue their […]

More


Medical

Medical Pharma Biotech MedTech - First-of-its-kind liver cancer research

First-of-its-kind liver cancer research

Health Industry Hub | July 13, 2020 |

Medical News: Primary liver cancer patients will benefit from a new research project in Western Australia that will apply the […]

More


News & Trends - Biotechnology

Biotech News - Australian researchers' cancer vaccine shows early promise

Australian researchers’ cancer vaccine shows early promise

Health Industry Hub | July 13, 2020 |

Biotech News: Mater University of Queensland Researchers have achieved publication in the highly-ranked journal, Clinical and Translational Immunology detailing their […]

More